Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Study of ALPN-101 in Systemic Lupus Erythematosus
Conditions
Interventions
ALPN-101
Placebo
Locations
46
United States
Investigational Site (107)
Anniston, Alabama, United States
Investigational Site (189)
Phoenix, Arizona, United States
Investigational Site (155)
Los Angeles, California, United States
Investigational Site (109)
San Diego, California, United States
Investigational Site (169)
Santa Barbara, California, United States
Investigational Site (106)
DeBary, Florida, United States
Start Date
June 22, 2021
Primary Completion Date
July 9, 2024
Completion Date
July 9, 2024
Last Updated
August 15, 2025
NCT07526350
NCT06875960
NCT06335979
NCT06647069
NCT07371468
NCT05843643
Lead Sponsor
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions